Imatinib mesylate
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Progressive Gastrointestinal Stromal Tumor
Conditions
Progressive Gastrointestinal Stromal Tumor
Trial Timeline
Oct 1, 2006 → Nov 1, 2012
NCT ID
NCT00510354About Imatinib mesylate
Imatinib mesylate is a approved stage product being developed by Novartis for Progressive Gastrointestinal Stromal Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00510354. Target conditions include Progressive Gastrointestinal Stromal Tumor.
What happened to similar drugs?
1 of 20 similar drugs in Progressive Gastrointestinal Stromal Tumor were approved
Approved (1) Terminated (4) Active (15)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01742299 | Approved | Active |
| NCT00867113 | Phase 2 | Completed |
| NCT00732784 | Phase 1 | Completed |
| NCT01172548 | Phase 2 | Completed |
| NCT01483014 | Phase 2 | Completed |
| NCT00684411 | Phase 2 | Completed |
| NCT01545427 | Phase 2 | Terminated |
| NCT00479934 | Phase 2 | Completed |
| NCT00677092 | Phase 2 | Completed |
| NCT00555581 | Phase 2 | Completed |
| NCT00510354 | Approved | Completed |
| NCT00427583 | Phase 2/3 | Terminated |
| NCT00124748 | Phase 3 | Terminated |
| NCT00171899 | Approved | Completed |
| NCT00171912 | Phase 2 | Completed |
| NCT00171977 | Approved | Completed |
| NCT00171938 | Phase 2 | Terminated |
| NCT00154349 | Phase 2 | Completed |
| NCT00237172 | Phase 2 | Completed |
| NCT00171860 | Phase 2 | Terminated |
Competing Products
20 competing products in Progressive Gastrointestinal Stromal Tumor